Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 17/20 | 0.74 |
| ▸ | PPARD | Q03181 | 4/20 | 0.62 |
| ▸ | PPARG | P37231 | 4/20 | 0.62 |
| ▸ | FABP2 | P12104 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6557473 | 0.89 | PPARA (0.70) | PPARAPPARDPPARGFABP2ALDH1A1 | |
| SCHEMBL6557445 | 0.89 | PPARA (0.69) | PPARAPPARDPPARGFABP2ALDH1A1 | |
| SCHEMBL9119675 | 0.89 | PPARA (0.93) | PPARAPPARDPPARGFABP2ALDH1A1 | |
| SCHEMBL6558046 | 0.89 | PPARA (0.93) | PPARAPPARDPPARGFABP2ALDH1A1 | |
| SCHEMBL1304559 | 0.88 | PPARA (0.80) | PPARAPPARDPPARGFABP2ALDH1A1 | |
| SCHEMBL6555955 | 0.85 | PPARA (0.71) | PPARAPPARDPPARGFABP2ALDH1A1 | |
| SCHEMBL9120807 | 0.83 | PPARA (0.71) | PPARAPPARDPPARGFABP2ALDH1A1 | |
| SCHEMBL9119026 | 0.82 | PPARA (0.74) | PPARAPPARDPPARGFABP2ALDH1A1 | |
| SCHEMBL3690900 | 0.82 | PPARA (0.74) | PPARAPPARDPPARGFABP2ALDH1A1 | |
| SCHEMBL8269751 | 0.82 | PPARA (0.73) | PPARAPPARDPPARGFABP2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8048896-B2 | Inhibit nonenzymatic formation of advanced glycation end-products (AGE) using e.g. aminoguanidine, OPB-9195 [(+/-)-2-isopropylidenehydrazono-4-oxo-thiazolidin-5-yla cetanilide], pyridoxamine, antioxidants, alagebrium, antihypertensives, angiotensin-converting enzyme inhibitors | Cell Viable Corporation (US) | 2011-11-01 | — | — | US | claimed |
| EP-1165064-B1 | NOVEL INHIBITORS OF FORMATION OF ADVANCED GLYCATION ENDPRODUCTS (AGE'S) | HOPE CITY (US) | 2004-02-25 | — | — | EP | claimed |
| US-6337350-B1 | CROSSLINKING INHIBITION OF PROTEINS | CITY OF HOPE | 2002-01-08 | — | — | US | claimed |
| EP-1165064-A2 | NOVEL INHIBITORS OF FORMATION OF ADVANCED GLYCATION ENDPRODUCTS (AGE'S) | City of Hope (US) | 2002-01-02 | — | — | EP | claimed |
| WO-2000059875-A2 | NOVEL INHIBITORS OF FORMATION OF ADVANCED GLYCATION ENDPRODUCTS (AGE'S) | CITY OF HOPE (US) | 2000-10-12 | — | — | WO | claimed |
| US-8053449-B2 | Method for inhibiting AGE complex formation | Cell Viable Corporation (US) | 2011-11-08 | — | — | US | disclosed |
| US-8048896-B2 | Inhibit nonenzymatic formation of advanced glycation end-products (AGE) using e.g. aminoguanidine, OPB-9195 [(+/-)-2-isopropylidenehydrazono-4-oxo-thiazolidin-5-yla cetanilide], pyridoxamine, antioxidants, alagebrium, antihypertensives, angiotensin-converting enzyme inhibitors | Cell Viable Corporation (US) | 2011-11-01 | — | — | US | disclosed |
| US-20080076804-A1 | METHODS FOR INHIBITING AND BREAKING AGE COMPLEX FORMATION | Cell Viable Corporation | 2008-03-27 | — | — | US | disclosed |
| US-20070099966-A1 | Device and Method for Inhibiting AGE Complex Formation | Cell Viable Corporation | 2007-05-03 | — | — | US | disclosed |
| WO-2007044309-A2 | DEVICE AND METHOD FOR INHIBITING AGE COMPLEX FORMATION | VASIX CORPORATION (US) | 2007-04-19 | — | — | WO | disclosed |
| EP-1468680-A2 | Using allosteric hemoglobin modifiers to decrease oxygen affinity in blood | Virginia Commonwealth University Intellectual Property Foundation, Inc. (US) | 2004-10-20 | — | — | EP | disclosed |
| EP-0585366-B1 | USING ALLOSTERIC HEMOGLOBIN MODIFIERS TO DECREASE OXYGEN AFFINITY IN BLOOD | UNIV VIRGINIA COMMONWEALTH (US) | 2004-04-28 | — | — | EP | disclosed |
| US-5432191-A | Ring-substituted phenoxymethyl /or substituted methyl/ carboxylates | THE CENTER FOR INNOVATIVE TECHNOLOGY (US) | 1995-07-11 | — | — | US | disclosed |
| EP-0585366-A4 | USING ALLOSTERIC HEMOGLOBIN MODIFIERS TO DECREASE OXYGEN AFFINITY IN BLOOD. | CT FOR INNOVATIVE TECHNOLOGY (US) | 1994-03-17 | — | — | EP | disclosed |
| EP-0585366-A1 | USING ALLOSTERIC HEMOGLOBIN MODIFIERS TO DECREASE OXYGEN AFFINITY IN BLOOD | CENTER FOR INNOVATIVE TECHNOLOGY (US) | 1994-03-09 | — | — | EP | disclosed |
| US-5290803-A | Using allosteric hemoglobin modifiers to decrease oxygen affinity in blood | THE CENTER OF INNOVATIVE TECHNOLOGY (US) | 1994-03-01 | — | — | US | disclosed |
| US-5250701-A | 2-(Phthalomidomethylphenoxyalkanoic acid or ester; wound healing agents; antiischemic agents; blood storage; antidepressants; Alzheimer's disease; schizophrenia | CENTER FOR INNOVATIVE TECHNOLOGY (US) | 1993-10-05 | — | — | US | disclosed |
| US-5248785-A | Using allosteric hemoglobin modifiers to decrease oxygen affinity in blood | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1993-09-28 | — | — | US | disclosed |
| WO-1992020335-A1 | USING ALLOSTERIC HEMOGLOBIN MODIFIERS TO DECREASE OXYGEN AFFINITY IN BLOOD | CENTER FOR INNOVATIVE TECHNOLOGY (US) | 1992-11-26 | — | — | WO | disclosed |
| US-5122539-A | Allosteric hemoglobin modifiers useful for decreasing oxygen affinity and preserving oxygen carrying capability of stored blood | CENTER FOR INNOVATIVE TECHNOLOGY (US) | 1992-06-16 | — | — | US | disclosed |